Stockhead
Regimen I of Neurizon Therapeutics’ ALS Platform Trial will increase its total patient cohort by 50% to 240 participants. ... Read More The post Neurizon ALS trial expands cohort to 240 patients as enrolment accelerates appeared first on Stockhead .
Go to News Site